Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells | Zendy

Jae H. Park | Zendy; Fabián Andrés Rosas Romero | Zendy; Ying Taur | Zendy; Michel Sadelain | Zendy; Renier J. Brentjens | Zendy; Tobias M. Hohl | Zendy; Susan K. Seo | Zendy

Open Access

Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells

Author(s) -

Jae H. Park,

Fabián Andrés Rosas Romero,

Ying Taur,

Michel Sadelain,

Renier J. Brentjens,

Tobias M. Hohl,

Susan K. Seo

Publication year - 2018

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciy152

Subject(s) - medicine , cytokine release syndrome , chimeric antigen receptor , immunology , leukemia , cd19 , acute lymphocytic leukemia , refractory (planetary science) , antigen , cancer , immunotherapy , lymphoblastic leukemia , biology , astrobiology

Chimeric antigen receptor (CAR)-modified T cells that target the CD19 antigen present a novel promising therapy for the treatment of relapsed B-cell acute lymphoblastic leukemia (B-ALL). Although cytokine release syndrome (CRS) and neurotoxicity have emerged as predominant noninfectious complications of CD19 CAR T-cell therapy, infections associated with this treatment modality have not been well documented.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research